CBFb-SMMHC is expressed in 8% of acute myeloid leukemias and inhibits AML1/RUNX1. In this study, murine marrow or human CD34
Introduction
CBFb-SMMHC, encoded by the inv (16) or t(16;16) translocated chromosomes in approximately 8% of acute myeloid leukemia (AML) cases, is a fusion protein containing amino acids 1-165 of the 182-residue core binding factor b (CBFb) and the rod domain of smooth muscle myosin heavy chain (SMMHC). 1, 2 CBFb does not bind DNA on its own, but increases the affinity of the CBFa subunits, AML1/RUNX1, AML2/RUNX3, and AML3/ RUNX2, for DNA via interaction with their DNA-binding Runt domains. 3, 4 The complex of CBFa subunits with CBFb is termed core binding factor (CBF). The CBFb segment within CBFb-SMMHC retains the ability to interact with AML1 and to facilitate DNA binding. 5, 6 Deletion of amino acids 2-11 from CBFb-SMMHC prevent its interaction with AML1. 7 The SMMHC segment of CBFb-SMMHC varies among human leukemia cases but most commonly contains a 404-residue ahelical rod domain and an eight or 41-residue nonhelical, Cterminal tailpiece generated by alternative splicing. 1, 8 The rod domains of myosins dimerize as coiled-coils, due to interactions mediated by their hydrophobic face, and then multimerize into filaments. Multimers of CBFb-SMMHC can sequester AML1 away from chromatin, which may account in part for CBFb-SMMHC-mediated inhibition of AML1-regulated genes; interaction of corepressors with the C-terminal assembly competence domain (ACD) of SMMHC may also be required. 9, 10 Multimerization of CBFb-SMMHC and inhibition of AML1 activities depend upon the integrity of the evolutionarily conserved, 28-residue ACD. 11, 12 CBFb-SMMHC inhibits proliferation of the 32Dcl3 myeloid and Ba/F3 lymphoid cell lines, dependent upon interaction with AML1 and integrity of the ACD. 6, 7, 12 Inhibition of proliferation is an unexpected phenotype for an oncoprotein, and the role of CBF and CBFb-SMMHC in regulating the proliferation of normal, primary marrow progenitor cells has not been well characterized. Mice lacking AML1 or CBFb do not develop definitive hematopoiesis and die as embryos. 2 Adult mice lacking one functional copy of AML1 had a mild reduction of myeloid colony-forming units (CFUs) in one study but a 50% increase in another, although progenitor proliferation in vitro was unaffected. 13, 14 Of note, CBFb-SMMHC is expected to inhibit all three AML1 family members, each of which could stimulate proliferation. Embryonic stem cells carrying a CBFb-SMMHC knock-in allele contribute to the erythroid but not the myeloid or lymphoid lineages. 15 Whether this observation reflects a specific effect on myeloid and lymphoid differentiation, proliferation, or survival is not known, nor has the effect of exogenous AML1 on these parameters been assessed.
In this study, we demonstrate that CBFb-SMMHC slows the proliferation of normal, primary murine and human myeloid progenitors due to inhibition of AML1, whereas erythroid progenitors were not inhibited. Decreased proliferation depended upon integrity of 10 amino acids in the CBFb domain required for interaction with AML1 and upon the 28-residue, Cterminal ACD. Conversely, AML1-ER, in which AML1 activity is induced by interaction of 4-hydroxytamoxifen (4HT) with the estradiol receptor (ER) domain, increased proliferation of murine myeloid progenitors in liquid culture. The implications of these findings for transformation by CBFb-SMMHC, regulation of cell proliferation during hematopoiesis by AML1, and the development of therapeutics that target CBFb-SMMHC will be discussed.
Materials and methods

Viral vectors
cDNAs encoding INV, INV(DACD), and INV(D2-11) were subcloned into the pBabePuro polylinker as BamHI/XhoI framgents, downstream of the Moloney murine leukemia virus (MMLV) long-terminal repeat (LTR), to generate retroviral vectors and into pEF.GFP, downstream of the elongation factor 1a (EF1a) promoter by blunt cloning into an EcoRV site, to generate self-inactivating (SIN) lentiviral vectors. 16, 17 Puromycin resistance is expressed from an internal simian virus 40 (SV40) promoter in pBabePuro and green fluorescence protein (GFP) from a cytomegalovirus (CMV) promoter in pEF.GFP. pBabePuro-AML1ER was previously described, 18 and the AML1ER cDNA was also transferred to pEF.GFP. These vectors were packaged by transient transfection into 293T cells together with packaging plasmids, at a ratio of 8 mg pBabePuro:2 mg pEcokat or 3 mg pEF.GFP:4.5 mg pCMV-DR8.91:1.5 mg pMD.G(VSV.G) per 100 mm dish, using 20 ml Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). 17, 19 293 T cells were grown in Dulbecco's modified Eagle's medium (DMEM) with 10% heat-inactivated fetal bovine serum (HI-FBS) and pen/ strep. A 5 ml portion of supernatant was collected 48 and 72 h after transfection, pooled, filtered through a 0.45 mm filter, aliquoted, and stored at À801C. Lentiviral vectors were concentrated 200-fold before freezing using a Centricon Plus-20 filter apparatus (Millipore, Bedford, MA, USA), which had been prewashed with 70% ethanol and phosphate-buffered saline (PBS).
Transduction
Female 7-to 10-week-old C57BL/6 mice were injected intraperitoneally with 150 mg/kg 5-fluorouracil (5-FU) in normal saline. p15(À/À) mice, kindly provided by M Barbacid and A Pellicer, 20 were treated similarly. After 6 days, marrow was flushed from their long bones, subjected to red cell lysis with NH 4 Cl, washed with PBS, and cultured in Iscove's modified Dulbecco's medium (IMDM) with 10% (HI-FBS), pen/strep, 10 ng/ml murine interleukin-3 (IL-3), 10 ng/ml murine IL-6, and 50 ng/ml murine stem cell factor (SCF, Peprotech, Rocky Hill, NJ, USA), 10 6 cells per 2 ml, at 371C, 5% CO 2 . Retroviral supernatant (1 ml) was then added to each 2 ml of cells with 4 mg/ml Polybrene for 2 additional days. The cells were then diluted to 10 6 per ml in the same media with 2 mg/ml puromycin. After 48 h, at which point 499% of untransduced cells were killed, approximately 20% of transduced cells were viable with each vector. Dead cells were removed by centrifugation through a layer of Lympholyte-M polysucrose (Cedarlane Labs, Ontario, Canada), and viable cells were washed twice with media. In some experiments these cells were cultured directly, while in others they were first subjected to lineage depletion using immunomagnetic beads and a cocktail of lineage antibodies (B220, CD5, Mac-1, Ter119, Gr-1, and 7-4) designed to enrich murine stem-progenitors (Stem Cell Technologies, Vancouver, Canada). After lineage depletion, 98% of cells were negative for the Mac-1 and Gr-1 myeloid antigens, compared with approximately 70% Mac-1 þ and 20% Gr-1 þ prior (not shown); typical yield was 3-5% of total mononuclear cells. Cells were either plated in methylcellulose with IMDM and 15% HI-FBS (Methocult 3234, Stem Cell Technologies) or in liquid culture with IMDM and 10% HI-FBS; in either case, the medium was supplemented with IL-3, IL-6, SCF. 200 nm 4HT or the ethanol vehicle was added to the cultures where indicated.
Human cord blood CD34 þ cells (AllCells Inc., San Mateo, CA, USA) or cryopreserved human mobilized peripheral blood CD34 þ cells from the Johns Hopkins cell bank (from donors who gave informed consent on an IRB-approved protocol) were placed directly in serum-free QBSF-60 media (Quality Biological Inc., Gaithersburg, MD, USA) with 100 ng/ml human SCF, 100 ng/ml FLT-3 ligand, and 20 ng/ml human thrombopoietin (TPO, Peprotech), or were first stained with a cocktail of FITCconjugated antibodies (CD38, CD33, CD13, CD41a, CD71, CD235A (glycophorin A), CD19, CD3, CD4, CD8, CD45RA, CD16, CD66B, CD14, CD10) and PE-anti-CD34 (BD Biosciences, San Diego, CA, USA) and FACS-sorted. The 10% of CD34 þ cells staining most weakly for the other antibodies were selected as CD34 þ lin À/low cells. These cells were transduced with lentiviral vectors at a multiplicity of infection of 3-5 in the presence of 4 mg/ml polybrene, for 3 consecutive days, after titering the viral stocks using 293T cells. On the fourth day, GFP þ cells, representing approximately 30% of the population with each vector, were isolated by FACS and cultured either in methylcellulose with IMDM and 30% HI-FBS (Methocult H4534, Stem Cell Technologies) or in liquid culture with IMDM and 10% HI-FBS, in either case with 50 ng/ml human SCF, 10 ng/ml human GM-CSF, 10 ng/ml human IL-3, and 5 U/ml human erythropoietin (Epo, Amgen, Thousand Oaks, CA, USA). In another set of experiments, the CD34 þ cells were stained with PE-anti-CD34 and FITC-anti-[CD33/CD13/CD64] and FACS-sorted to obtain an enriched committed myeloid progenitor fraction, or with PE-anti-CD34 and CyC-anti-[CD71/ CD235A] to obtain an enriched committed erythroid progenitor fraction. These two populations were then transduced and FACS-sorted for GFP þ cells and cultured in methylcellulose or liquid culture as described above for CD34 þ cells.
Proliferation and differentiation of transduced cells
Western blotting, to confirm expression, was carried out using CBFb antiserum as described, 12 using extracts from equal numbers of Ba/F3 cells transduced with retroviral vectors and selected for 7 days with puromycin, or K562 cells 5 days after transduction with lentiviral vectors, or from transduced, puromycin-selected murine marrow cells. Transduced murine cells were cultured at 10 000 cells/ml in methylcellulose, lineage depleted murine cells at 3000 cells/ml, and human CD34 þ or CD34 þ lin À/low cells at 1000 cells/ml. Transduced murine or human cells were seeded at 2 Â 10 5 cells/ml in liquid culture. Myeloid and erythroid CFUs were enumerated on day 8 for murine cells and on day 14 for human cells. Colonies were visualized by phase and fluorescence microscopy using a Nikon TE300 microscope at Â 40 magnification at room temperature and were photographed with a Diagnostics Instruments Spot camera. The images were acquired using Spot 3.3.2 software. Viable cell counts in liquid culture were enumerated using Trypan blue dye. To assess myeloid differentiation, murine cells were stained with PE-anti-Mac-1 or PE-anti-Gr-1, and human cells with PE-anti-CD33 or PE-anti-CD14, and subjected to FACS analysis. For cell cycle analysis, cells were washed and resuspended in PBS containing 0.56% NP-40, 3.7% formaldehyde, and 11 mg/ml Hoechst 33258 (Sigma, St Louis, MO, USA)28-amino-acid ACD prevents multimerization via the SMMHC segment and prevents interaction with the mSin3a corepressor. cDNAs encoding INV, INV(DACD), and INV(D2-11) were transferred to the pBabePuro retroviral vector (Figure 1b) . Expression from these vectors was evaluated in the murine Ba/ F3 hematopoietic cell line and in transduced murine marrow. Equal numbers of cells were loaded in each lane, as indicated by the signal obtained from the nonspecific cross-reactive material, although INV from murine bone marrow was apparently underloaded by comparison with endogenous CBFb. The levels obtained were compared with those present in ME-1 cells. 21 This cell line was derived from a patient with inv(16)-associated AML (Figure 1c , left panels). INV and INV(D2-11) were expressed at similar levels in Ba/F3 cells, and INV(DACD) was expressed at a two-to three-fold higher level. In murine myeloid progenitors, D2-11 was expressed approximately twofold lower than INV and DACD at similar levels relative to CBFb. Expression was not assessed in human CD34
þ cells due to the limited number of cells obtained after flow cytometry. Expression of exogenous INV was quantitatively similar to that observed in ME-1 human leukemia cells. INV in ME-1 cells has slightly slower mobility as these cells express the INV splice variant harboring a longer nonhelical myosin tailpiece. Both INV isoforms are present in leukemic blasts and each inhibits Ba/F3 cell proliferation similarly. 7, 8 The band at about 60 kDa in the ME-1 lanes represents proteolysis. Expression of INV was similar to CBFb in murine marrow, as might also occur in leukemic blasts due to translocation of one CBFb locus. Although D2-11 was expressed at a lower level than INV in murine marrow cells, it may be expressed in excess of endogenous AML1, as the predominantly cytoplasmic expression of CBFb potentially reflects markedly increased expression relative to AML1. 12 Proliferation of murine myeloid progenitors transduced with these three INV proteins or with the pBabePuro control vector was assessed in liquid culture with IL-3, IL-6, and SCF ( Figure 2a , top panels). Cell counts from a representative experiment are shown. In addition, the ratio of cells in the control (Puro) culture divided by the number of cells in the INV, DACD, or D2-11 cultures on day 4 was calculated. Intact INV inhibited proliferation more than three-fold, on average, whereas INV(DACD) and INV(D2-11) had little effect. In the same set of experiments, transduced cells were also plated in methycellulose cultures containing the same growth factor cocktail of IL-3, IL-6, and SCF (Figure 2b, top panel) . INV reduced the number of myeloid CFUs three-fold, and the effect of INV was significantly greater than DACD or D2-11. Erythroid cell proliferation was not assessed in these assays as Epo was not included in the media. In an earlier study, we had found that very few erythroid, compared to myeloid, colonies are generated from adult murine marrow even in the presence of Epo. 22 In a separate set of experiments, progenitors transduced with Puro or INV were subjected to lineage depletion prior to culture in liquid or methylcellulose (Figure 2a and b, bottom panels). INV specifically inhibited proliferation in both settings.
The few myeloid colonies generated in methylcellulose from INV-transduced cells were strikingly smaller than those generated by control, pBabePuro-transduced cells (Figure 3a , left) or with the INV(D2-11) or INV(DACD) variants (not shown).
Myeloid differentiation of Puro-and INV-transduced, lineage depleted murine marrow cells was assessed by FACS analysis (Figure 3b, left) . Gr-1 and Mac-1 were each detected on the surface of 40% of the cells by day 2 and 90% by day 4 of (Figure 4a and b, top panel). INV inhibited proliferation 2.6-fold in liquid culture, on average, and reduced the number of myeloid CFU by 1.6-fold (31%), without affecting the number of BFU-E. Greater than 90% of cells in liquid cultures were myeloid, based on WrightGiemsa staining of cell cytospins (not shown). INV(D2-11) and INV(DACD) had no effect on proliferation of human myeloid progenitors in liquid culture. In methylcellulose culture, the number of CFU obtained after transduction with DACD was increased compared with INV with only borderline significance (Po0.08). On the other hand, D2-11 was significantly less effective than INV at inhibiting the proliferation of human myeloid CFU, underscoring the role of AML1 in regulating human progenitor proliferation.
In an additional set of experiments, CD34
þ lin À/low cells transduced with INV or GFP lentiviral vectors were plated in methylcellulose. INV inhibited the number of myeloid colonies obtained by approximately two-fold, without affecting the number of BFU-E (Figure 4b, bottom left) .
The majority of human colonies transduced with lentiviral vectors expressed GFP, as assessed by fluorescence microscopy. Human myeloid colonies expressing INV were much smaller than either the occassional GFP-negative colony observed on the same dish or colonies from cells that had been transduced with the control EF.GFP lentiviral vector (Figure 3a, right) . Colonies obtained with the D2-11 or DACD mutants were similar in size to those obtained with the control GFP vector (not shown). Results shown were obtained using adult mobilized peripheral blood CD34 þ cells. Myeloid CFU from CD34 þ cord blood cells were also inhibited by INV in number (three-fold) and size, whereas BFU-E were unaffected.
Myeloid differentiation of GFP-and INV-transduced CD34 
INV inhibits cell cycle progression in myeloid progenitors
Murine mononuclear cells transduced with pBabePuro or with pBabePuro-INV were selected with puromycin. Viable cells were then isolated, subjected to lineage depletion, and placed in liquid culture with IL-3, IL-6, and SCF. Cell cycle analysis was carried out on day 2 of liquid culture (Figure 5a ). The G1/S ratio for the INV-transduced culture was increased by 1.4-fold (40%), as compared with the G1/S ratio in the Puro culture. Human CD34 þ cells transduced with GFP, INV, INV(D2-11), or INV(DACD) were subjected to cell cycle analysis 2 days after flow cytometry (Figure 5b) . INV increased the G1/S ratio in human progenitors 1.4-fold, relative to the GFP control, whereas DACD or D2-11 had little effect (Figure 5a ). Thus, INV slows the cell cycle in primary human and murine myeloid progenitors, dependent upon interaction with CBFa subunits and on the integrity of the ACD. Of note, INV did not increase the number of apoptotic cells, which would have been detected as cells with sub-2n DNA content to the left of the G1 peak, in the experiment shown (Figure 5b ) and in other experiments with murine or human cells (not shown).
As the promoter of the p15INK4b gene is often inactivated by methylation in AML cases whereas expression of p16 is more often reduced in ALL, 23 we sought to determine whether loss of this cyclin-dependent kinase (cdk) inhibitor would prevent inhibition of proliferation by INV. Mononuclear cells from p15(À/À) mice transduced with the Puro or INV retroviral vectors were placed in liquid or methylcellulose cultures with IL-3, IL-6, and SCF. Marrow cells from p15( þ / þ ) mice were transduced in the same experiments (Figure 5c ). Inhibition of proliferation by INV in p15(À/À) myeloid progenitors was similar to that observed in p15( þ / þ ) progenitors, indicating that loss of p15 is not sufficient to overcome the cell cycle inhibition that results from inhibition of AML1 by INV. 
CBFb-SMMHC inhibits myeloid proliferation
J D'Costa et al
AML1 stimulates proliferation of murine myeloid progenitors in liquid culture
Since INV inhibits proliferation of myeloid progenitors via inhibition of AML1, we sought to determine whether, conversely, exogenous AML1 would be sufficient to stimulate their proliferation. Total or lineage-negative murine marrow cells transduced with AML1-ER and exposed to 4HT accumulated to a two-fold higher cell number over 1 week (Figure 6 ), whereas exposure of control, pBabePuro-transduced marrow to 4HT reduced proliferation by 40% over 7 days (not shown). The effect on murine progenitors in liquid culture was reproducible in three separate experiments. However, AML1-ER did not alter the frequency of CFUs.
Discussion
The major conclusion of this study is that CBFb-SMMHC inhibits cell cycle progression in normal, primary murine and human myeloid progenitors, independent of induction of apoptosis or blockade of myeloid differentiation. This effect depends upon inhibition of AML1-regulated genes and upon integrity of the CBFb-SMMHC C-terminal ACD domain. These results with normal cells support efforts to target the AML1:CBFb-SMMHC complex, interaction of the ACD with corepressors, or ACDmediated multimerization to develop novel therapies for AML cases expressing CBFb-SMMHC. In addition, the finding that CBFb-SMMHC, but not the D2-11 mutant, slows progenitor proliferation while AML1-ER accelerates proliferation implicates AML1 as a regulator of the cell cycle in normal murine and human myeloid progenitor cells. The effect of AML1 inhibition on proliferation was greater than AML1 overexpression, indicating that AML1 is required for progenitor cell cycle progression but that additional factors are required to potently enhance proliferation.
The three-to four-fold inhibition of cell accumulation by CBFb-SMMHC in liquid culture is substantial in the context of the observed absolute increase of five-fold for vector-transduced murine marrow cells and of 20-fold for vector-transduced CD34 þ human cells, over the same period. The marked reduction in the size of myeloid CFUs expressing CBFb-SMMHC increases the significance of the two-to four-fold decrease in myeloid colony numbers observed. Inhibition of proliferation was retained when more immature, lineage depleted cells were assayed. Lack of BFU-E suppression by CBFb-SMMHC correlates with the absence of AML1 in the erythroid hematopoietic subset, is consistent with the presence of CBFb-SMMHC in the erythroid precursors of murine knockin chimeras, and confirms that the cell cycle inhibitory effect of CBFb-SMMHC in myeloid progenitors is physiologically relevant rather than nonspecific. 14, 15 Lack of cell cycle inhibition by the D2-11 mutant, together with the increased proliferation observed with AML1-ER, indicates that CBFb-SMMHC inhibits the cell cycle in normal progenitors by reducing the activity of AML1. We have found that AML1 transactivates the promoter of the murine cyclin D3 gene, that CBFb-SMMHC or AML1-ETO reduces expression of cyclin D2 and cyclin D3 mRNA in Ba/F3 cells, 24 and that AML1 transactivates the human D3 promoter approximately six-fold (F Bernardin-Fried and ADF, unpublished). Interestingly, mice lacking cyclin D2 have reduced B cells, those lacking cyclin D3 have reduced T cells, and mice lacking cyclins D1, D2, and D3 have a marked reduction of lymphoid, erythroid, and myeloid progenitors and hematopoietic stem cells. 25 In addition, CBFb-SMMHC rapidly inhibits cdk4 expression in Ba/F3 cells, and cyclin D2 or cdk4 prevents cell cycle inhibition in that model. 18 In future studies, we intend to determine whether AML1 binds and regulates each of the cyclin D or cdk4 genes in CBFb-SMMHC inhibits myeloid proliferation J D'Costa et al normal progenitor/stem cells. It will also be of interest to assess the role of AML1 in pluripotent hematopoietic stem-progenitor cell proliferation and cell cycle entry and to investigate how erythroid progenitors differ with respect to cell cycle control.
Loss of the p15 cdk inhibitor did not prevent inhibition of proliferation by CBFb-SMMHC in murine progenitors. c-Myc levels are elevated in 30% of AML cases, often due to indirect effects such as activation of receptor tyrosine kinases, and exogenous c-Myc can also overcome CBFb-SMMHC-mediated cell cycle inhibition in Ba/F3 cells. 26 Perhaps the combination of p15 loss and overexpression of c-Myc or other factors that stimulate S-phase entry is especially effective in overcoming inhibition of cyclin D and/or cdk4 expression by CBFb-SMMHC in myeloid progenitors, allowing CBFb-SMMHC to then contribute to transformation by blocking differentiation and/or apoptosis. Consistent with this model, combining CBFb-SMMHC with loss of both p16 and p19 leads to acute lymphoid leukemia in mice. 27 Inhibition of proliferation by CBFb-SMMHC was either prevented or reduced in the absence of the C-terminal ACD. We are currently studying a series of point mutations in the ACD domain in an effort to determine whether the ability of the ACD to help nucleate multimerization and/or to bind the mSin3A corepressor is critical for inhibition of CBF by CBFb-SMMHC. In either case, this study supports the possibility that targeting the ACD with a small molecule inhibitor would be useful for the therapy of AML cases associated with expression of CBFb-SMMHC, as inactivating the ACD would be expected to prevent CBFb-SMMHC from inhibiting AML1 and so contribute to leukemogenesis. Additional SMMHC domains or the CBFb:SMMHC junction might also serve as useful targets. 28, 29 Targeting the CBFb domain upstream of this junction is less appealing, as disruption of CBFa:CBFb complexes may significantly disrupt normal hematopoiesis. CBFb-SMMHC inhibits myeloid proliferation J D'Costa et al
